Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Behring's Dave Andrews

This article was originally published in The Gray Sheet

Executive Summary

Behring's Dave Andrews: Dies in TAM flight 402, which crashed en route from Sao Paulo to Rio de Janeiro, Brazil on Oct. 31. Andrews was Behring's vice president and regional manager of marketing for Canada, Latin America and the Caribbean...

You may also be interested in...



Immunocore Aims For $100m IPO After Immunotherapy Success

The UK biotech is set for a NASDAQ launch which could propel to its first commercial launch by 2022

Another Failure For Biohaven’s Troriluzole

Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.

RedHill On The Rise With Three Drugs And Potential COVID-19 Therapy

The Israeli biotech which is listed on the NASDAQ is in for a busy 2021 with strong marketing pushes for Movantik, Aemcolo and Talicia and completing a pivotal trial for COVID-19 hopeful opaganib.

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel